Richard Weaver will be presenting at the Making Pharmaceuticals exhibition and conference next week at the Ricoh Arena in Coventry.
Any research organisation working towards bringing a new medicine to market will want to know as early as possible “can this compound be a drug?” The key to this is sufficient potency against the target, an acceptable safety margin coupled with commensurate DMPK properties to allow a sufficiently low dose. At Making Pharmaceuticals, Richard will present on how DMPK understanding and influence is needed at the early stages of R&D and how a human dose prediction can be made early in drug discovery and refined in the pre-clinical development phase.
Making Pharmaceuticals will host over 2,000 visiting pharma professionals over the two days, and 200+ exhibitors from across Europe who gather at the event to meet, network, generate business and take advantage of more than 90 free to attend pharmaceutical conference sessions.
To find out more, visit the website.